重组Anti-MDM2 (phospho S166)抗体[EPR1450(2)]
Anti-MDM2 (phospho S166) antibody [EPR1450(2)]
- 20ul selling size
- RabMAb
- Recombinant
- 了解详情
Be the first to review this product! Submit a review
|
(16 Publications)
Rabbit Recombinant Monoclonal MDM2 phospho S166 antibody. Suitable for IHC-P, Dot, WB and reacts with Human, Synthetic peptide samples. Cited in 16 publications.
查看别名
E3 ubiquitin-protein ligase Mdm2, Double minute 2 protein, Oncoprotein Mdm2, RING-type E3 ubiquitin transferase Mdm2, p53-binding protein Mdm2, Hdm2, MDM2
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MDM2 (phospho S166) antibody [EPR1450(2)] (AB170880)
Immunohistochemical analysis of paraffin-embedded human gastric carcinoma tissue labeling MDM2 (phospho S166) using ab170880 at a 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MDM2 (phospho S166) antibody [EPR1450(2)] (AB170880)
Immunohistochemical analysis of paraffin-embedded human placenta tissue labeling MDM2 (phospho S166) using ab170880 at a 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
- WB
Supplier Data
Western blot - Anti-MDM2 (phospho S166) antibody [EPR1450(2)] (AB170880)
All lanes:
Western blot - Anti-MDM2 (phospho S166) antibody [EPR1450(2)] (ab170880) at 1/50000 dilution
Lane 1:
MCF7 cell lysate at 10 µg
Lane 2:
MCF7 cell lysate treated with IGF-1 at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit IgG at 1/2000 dilution
Predicted band size: 55 kDa,62 kDa
Observed band size: 55 kDa
false
- WB
Lab
Western blot - Anti-MDM2 (phospho S166) antibody [EPR1450(2)] (AB170880)
Diluting and blocking buffer : 2% BSA/TBST
The molecular weight is the same with the one from this paper PMID : 25392082
All lanes:
Western blot - Anti-MDM2 (phospho S166) antibody [EPR1450(2)] (ab170880) at 1/100000 dilution
Lane 1:
A549 (Human lung carcinoma epithelial cell) whole cell lysate at 15 µg
Lane 2:
A549 (Human lung carcinoma epithelial cell) treated with insulin at 1ug/ml for 150 minutes. Whole cell lysate at 15 µg
Lane 3:
A549 (Human lung carcinoma epithelial cell) treated with insulin at 1ug/ml for 150 minutes. Whole cell lysate. Then the membrane was incubated with phosphatase at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 55 kDa
Observed band size: 90-140 kDa
false
Exposure time: 5s
- Dot
Supplier Data
Dot Blot - Anti-MDM2 (phospho S166) antibody [EPR1450(2)] (AB170880)
Dot blot analysis of MDM2 (phospho S166) phospho peptide (Lane 1) MDM2 non-phospho peptide (Lane 2) labeling MDM2 (phospho S166) with ab170880 at a dilution of 1/1000. Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated (ab97051) was used as the secondary antibody at a dilution of 1/100000.
Blocking and dilution buffer : 5% NFDM/TBST.
Exposure time : 3 minutes.
- WB
CiteAb
Western blot - Anti-MDM2 (phospho S166) antibody [EPR1450(2)] (AB170880)
MDM2 (phospho S166) western blot using anti-MDM2 (phospho S166) antibody [EPR1450(2)] ab170880. Publication image and figure legend from Kou, F., Sun, H., et al., 2020, J Cancer, PubMed 32201520.
ab170880 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab170880 please see the product overview.
TOP2A is involved in p53 pathway. A. By analyzing GEO and TCGA databases, 148 mRNAs were found in TOP2A high and low groups. KEGG pathway enrichment analysis showed the top 3 most enriched pathways were Oocyte meiosis, p53 signaling pathway and Viral carcinogenesis, respectively. B. The heat map indicated significantly differentially expressed genes of P53 pathway between TOP2A-high and TOP2A-low group. CCNB1, CCNE2, CDK1, CCNB2, RRM2, CHEK1 and PMAIP1 were significantly upregulated in TOP2A high expression group. C. The expression levels of CCNB1, CCNB2 and CHEK1 were further identified by the violet plots, which demonstrated these genes expression levels were positively related to TOP2A. D. The expression levels of p53 related genes (cyclinB1 (CCNB1), cyclinB2 (CCNB2), CHEk1, MDM2, p53) in GLC82 and A549 cells with transfected TOP2A siRNA or control were identified by Western blot. Downregulation of the expression levels of CCNB1, CCNB2 and CHEk1 was observed in lung adenocarcinoma cells with siRNA compared with control. There was no difference in the expression levels of p53 and MDM2 between siRNA and control groups. These results indicated that TOP2A regulates the expression levels of p53 pathway related genes.
false
不同偶联物与剂型 (1)
-
Anti-MDM2 (phospho S166) antibody [EPR1450(2)] - BSA and Azide free
反应性数据
产品详情
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
性能和储存信息
形式
纯度
存储溶液
运输条件
推荐的短期储存时间
推荐的短期储存条件
推荐的长期储存条件
分装信息
储存信息
补充信息
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The MDM2 protein plays a central role in cell cycle control and apoptosis regulation. It forms a complex with p53 which modulates p53's stability and activity. By binding to p53 MDM2 prevents p53 from inducing cell cycle arrest or apoptosis in response to DNA damage or oncogenic signals. Its interaction allows cells to proliferate even in the presence of potential growth-arrest signals maintaining homeostasis under normal physiological conditions.
Pathways
MDM2 and p53 form a critical axis within the DNA damage response and tumorigenesis pathways. The p53-MDM2 feedback loop is a well-studied mechanism that balances cell survival and death. When DNA damage occurs p53 gets activated and in turn upregulates MDM2 expression creating a feedback loop. Other proteins like ARF also interact with MDM2 inhibiting its activity towards p53 and thereby enhancing p53 function during cellular stress.
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (16)
Recent publications for all applications. Explore the full list and refine your search
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11:e2405907 PubMed39324579
2024
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 25:218 PubMed37153032
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cells 11: PubMed35883700
2022
Applications
Unspecified application
Species
Unspecified reactive species
Acta pharmacologica Sinica 43:1033-1045 PubMed34188177
2021
Applications
Unspecified application
Species
Unspecified reactive species
Cell communication and signaling : CCS 19:22 PubMed33618712
2021
Applications
Unspecified application
Species
Unspecified reactive species
Bioscience reports : PubMed32869837
2020
Applications
Unspecified application
Species
Unspecified reactive species
Bioscience trends 14:83-95 PubMed32132307
2020
Applications
Unspecified application
Species
Unspecified reactive species
Journal of Cancer 11:2496-2508 PubMed32201520
2020
Applications
Unspecified application
Species
Unspecified reactive species
Oncogene 38:6142-6157 PubMed31289362
2019
Applications
Unspecified application
Species
Unspecified reactive species
Anatomical record (Hoboken, N.J. : 2007) 302:1544-1551 PubMed30809951
2019
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com